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Abstract
Synthesis of aza-rocaglates, nitrogen-containing analogues of the rocaglate natural products, is 
reported. The route features ESIPT-mediated (3+2) photocycloaddition of 1-alkyl-2-aryl-3-
hydroxyquinolinones with the dipolarophile methyl cinnamate. A continuous photoflow reactor 
was utilized for photocycloadditions. An array of compounds bearing the 
hexahydrocyclopenta[b]indole core structure was synthesized and evaluated in translation 
inhibition assays.
Graphical abstract
Aza-rocaglates were prepared from 3-hydroxyquinolinones and methyl cinnamate using ESIPT 
(3+2) photocycloaddition in a continuous photoflow reactor. A collection of compounds 
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containing hexahydrocyclopenta[b]indole core was synthesized using this method and evaluated in 
translation inhibition assays.
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Flavaglines are a family of natural products isolated from plants of the genus Aglaia which 
feature the cyclopenta[b]-benzofuran core structure.[1] After the first isolation of 
rocaglamide (1, Figure 1) by King and coworkers in 1982,[2] more than 100 natural 
flavaglines (rocaglates) have been isolated, characterized, and tested for insecticidal, anti-
inflammatory, and anticancer activities.[3] Due to their intriguing structural complexity and 
biological activities, a number of synthetic chemists have undertaken syntheses of natural 
flavaglines as well as targeted derivatives with improved or novel biological properties.[4]
However, with the exception of the carbocyclic analogue 4 for which biological data was not 
reported,[5] such studies have been limited to variations of the cyclopenta[b]benzofuran 
core.[4] Previously, we reported a biomimetic approach towards rocaglates using excited 
state intramolecular proton transfer (ESIPT)-mediated (3+2) photocycloaddition of 3-
hydroxyflavones and dipolarophiles.[6] Later, we successfully extended the methodology to 
employ 1,2-dimethyl-3-hydroxyquinolinone (DMQ, 6) to access various cycloadducts.[7] For 
example, photocycloaddition of DMQ (6) with methyl cinnamate 7 provided bridged ketone 
cycloadduct 8 (Scheme 1).
In the current study, we considered syntheses of nitrogen-containing rocaglate analogues 
employing ESIPT photocycloaddition of 2-aryl-3-hydroxyquinolinones such as 9 wherein it 
was thought that π-π stacking interactions between the 2-aryl substituent of substrate 9 and 
the phenyl group of methyl cinnamate 7 may favor the desired cycloaddition geometry 
(Scheme 2). Aza-aglain cycloadduct 10 may further undergo α-ketol (acyloin) 
rearrangement to 11 which may be followed by diastereoselective reduction to access aza-
rocaglates such as 5 bearing the hexahydrocyclopenta[b]-indole scaffold. Herein, we outline 
synthetic and mechanistic studies regarding the aza-rocaglates as well as translation 
inhibition studies of the natural product variants.
We first performed pilot studies with 2-aryl-3-hydroxyquinolinone substrate 12.[8b] Under 
photoirradiation of 12 with dipolarophile 7 (λ>330 nm), we did not observe satisfactory 
conversion to the corresponding cycloadduct 13 (Scheme 3). As our previous studies were 
performed using a N-methyl-3-hydroxyquinolinone substrate (cf. Scheme 1), 1-methyl-2-
aryl-3-hydroxyquinolinone (N-Me-3-HQ, 15) was chosen as a modified substrate for ESIPT 
photocycloaddition. The synthesis of derivatives related to 15 has been previously 
reported.[8] However, using substrate 14 and polyphosphoric acid (PPA) as solvent,[8b] a 
lengthy workup and purification was required and only 34% of the desired product 15 was 
observed. In order to obtain practical amounts of 15, development of a new method for the 
synthesis of N-alkyl-3-hydroxyquinolinones was required. After evaluation of reaction 
conditions, we found that treatment of phenacyl anthranilate 14 with NaH (1.0 equiv.) in 
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THF led to the production of 15 in 83% yield (Scheme 4A). A proposed mechanism 
(Scheme 4B) may proceed through formation of hemiaminal 14a followed by rearrangement 
to alkoxide 14b. 3,1-Benzoxazin-4-ones related to 14b have previously been reported from 
treatment of phenacyl anthranilates with acetic acid.[8c] Further reaction of 14b to iminium 
14c followed by isomerization should generate the intramolecular hydrogen bond-stabilized 
enolate 14d (Scheme 4C).[9] A DFT model of 14d (Scheme 4C) shows a well-defined 
arrangement for further transformations.[10] Cyclization of 14d to benzoxazepine 14e 
followed by rearrangement to zwitterion 14f, elimination, and acidic workup provides 3-
hydroxyquinolinone 15. Similar benzoxazepine structures have been reported previously in 
the literature by treatment of phenacyl anthranilates with phosphoryl chloride.[11] To the best 
of our knowledge, the synthesis of 1-alkyl-3-hydroxyquinolinones from phenacyl 
anthranilates under basic conditions has not been previously described.
When substrate 15 was subjected to photoirradiation (λ>330 nm) in the presence of methyl 
cinnamate, cycloadducts were indeed generated. After condition optimization, we found that 
using trifluorotoluene and trifluoroethanol as co-solvents, aza-aglain derivatives 16 and 17 
could be isolated in 40% yield (5:1 ratio). However, 48 h was needed to obtain the desired 
products in which case substantial decomposition was observed. Taking advantage of a 
recently developed continuous photoflow reactor,[12] we found that the reaction was 
complete in 9 h (46% yield, 89% yield b.r.s.m., 16:17= 5:1). In addition, significantly less 
decomposition was observed in comparison to batch reactions which facilitated product 
purification. Reduction of the minor isomer 17 using LiAlH4 provided an unstable diol 
which was acylated to afford the bis-para-bromobenzoate 18. The structure and relative 
stereochemistry of 18 was confirmed using HMBC and NOESY experiments.[10] Using 
sodium methoxide-mediated α-ketol rearrangement, followed by diastereoselective 
reduction, aza-rocaglate 20 could be obtained in 77% yield (2 steps) from cycloadduct 16. 
The structure of 20 was unambiguously confirmed by X-ray crystal structure analysis of the 
derived bromobenzoate 21 (Figure 2).[13] Interestingly, inspection of the X-ray structure 
reveals that the N-methyl moiety is coplanar to the adjacent aryl group indicating a non-
pyramidalized nitrogen.[14] This is likely due to steric interaction of N-methyl moiety with 
the two nearby aryl substituents which appears to prevent nitrogen pyramidalization.
In order to provide a plausible explanation for the differential reactivity of 3-
hydroxyquinolinones 12 and 15, we measured their UV-Vis absorption spectra.[15] We found 
that in CH2Cl2:MeOH (2:1), both substrates possess an absorption band at approximately 
370 nm which can be attributed to charge transfer excitation. More interestingly, we 
observed an additional absorption (310 nm) for substrate 12 (Figure 3). Therefore, we 
hypothesized that in solution, 12 may also be represented by an aromatic, 
dihydroxyquinoline tautomeric form which may diminish its photoreactivity.[16] In order to 
support this assertion, we synthesized 3,4-dimethoxyquinoline 22 by treatment of 12 with 
TMS diazomethane (Scheme 6) for evaluation of its UV absorption properties.[17] An 
absorption shoulder at 320 nm was also observed for compound 22 which provides 
information on the existence of tautomeric form 12a in solution.
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We next targeted the synthesis of more highly functionalized aza-rocaglates. Starting with 
N-Me-Br-3-HQ 23 as substrate, obtained from commercially available materials in four 
steps,[10] photocycloaddition with methyl cinnamate 7 in the continuous flow reactor led to 
the production of cycloadduct 24 in 43% yield and excellent selectivity.[18] Ketol 
rearrangement, followed by diastereoselective reduction, provided aza-rocaglate 26 in good 
yield. (Scheme 7) Compound 26 was then further transformed to the corresponding 
hydroxamate 27[19] by saponification and coupling.
As part of our study, we also targeted the synthesis of the N-H-containing aza-rocaglate 5. 
After an evaluation of nitrogen protecting groups for synthesis of 3-hydroxyquinolinone 
substrates, only alkyl protecting groups on the nitrogen could enable access to 
photocycloadducts (cf. Scheme 4). Therefore, an allyl protecting group was chosen to 
synthesize N-allyl-3-HQ 28 using the previously described method. Upon photoirradiation 
of substrate 28 in the continuous photoflow reactor, cycloadduct 29 could be obtained from 
N-allyl-3-HQ 28 in 43% yield (Scheme 8). Ketol rearrangement of 29 led to the production 
of 30 which was subjected to hydroxyl-directed reduction to afford N-allyl-aza-rocaglate 31. 
After a thorough evaluation of the allyl deprotection conditions, we found that using Pd (0) /
1,4-bis(diphenylphosphino)-butane complex and Meldrum’s acid as nucleophile and proton 
source,[20] N-H-aza-rocaglate 5 could be obtained in 45% yield. Other N-deallylation 
conditions reported in the literature failed to provide the desired product.[21] In order to 
demonstrate the possibility for further functionalization of the N-allyl moiety, 31 was 
converted into acrylate 32 using olefin cross metathesis.[22]
Rocaglates have been shown to behave as potent inhibitors of translation by interfering with 
the activity of eukaryotic initiation factor (eIF) 4A, an RNA helicase necessary for cap-
dependent protein synthesis.[23] We therefore assessed the biological activities of 
compounds 5, 26, 27, 31, and 32 in vitro in a translation assay programmed with the 
bicistronic mRNA, FF/HCV/Ren (Figure 4A). In this system firefly luciferase (FF) 
production is eIF4A-dependent whereas Renilla luciferase (Ren) is not.[24] Silvestrol (not 
shown) and rocaglates CR-1-31B[19a] and SDS-1-021-(−)[3e] potently inhibited FF 
production (5–10 fold) at 5 μM. The only aza-rocaglate to affect FF production was the N-
methyl derivative 26, showing a ~30% reduction in FF production at 20 μM (Figure 4A). To 
assess activity towards cellular protein synthesis, HeLa cells were incubated with silvestrol, 
CR-1-31B, or 26 for 1 h and metabolic protein synthesis quantitated (Figure 4B). Whereas 
100 nM silvestrol or CR-1-31B completely blocked protein synthesis, compound 26 showed 
modest activity at only at 50 μM (~20% inhibition).
Consistent with these findings, we also found no evidence for translation inhibition over a 24 
h period at concentrations up to 10 μM using a whole cell assay based on constitutive 
expression of the rapidly turned-over reporter protein firefly luciferase (Figure 5A). 
Likewise the compounds had minimal cytotoxic activity in a standard 3-day growth assay 
over the same concentration range (Figure 5B). Together, these results indicate that aza-
rocaglates do not possess the same inhibitory potency towards protein synthesis in 
comparison to related rocaglates such as RHT.[19c]
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In summary, we have employed ESIPT photocycloaddition methodology to synthesize aza-
rocaglates. Our studies have uncovered differential photocycloaddition reactivities between 
N-H- and N-Me-substituted 2-aryl-3-hydroxyquinolinone substrates. A novel method to 
access 1-alkyl-2-aryl-3-hydroxyquinolinones was also developed for (3+2) 
photocycloaddition. Use of a continuous photoflow reactor facilitated synthesis of aza-
rocaglates with both N-alkyl and N-H substitution. Initial protein synthesis and translation 
inhibition data indicates that aza-rocaglates do not possess activity in comparison to related 
rocaglates which provides further information on the SAR of the natural product scaffold.
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Rocaglate and Related Natural Products, a Carbocyclic Analogue, and Aza-Rocaglate 
Structures.
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Synthesis and X-ray Crystal Structure of Aza-Rocaglate 21.
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UV Absorption Spectra of 3-Hydroxyquinolinones 12 and 15 in Comparison to 
Dimethoxyquinoline 22.
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A. Effect of aza-rocaglates on in vitro translation of FF/HCV/Ren. B. Assessing translation 
inhibition activity of 26 on HeLa cells.
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A. Translation inhibition (10 μM) in whole cells based on constitutive expression of firefly 
luciferase. B. 3-day growth assay (Human 293T cancer cells) over the same concentration.
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Previous Studies on Photocycloadditions Using 3-Hydroxyquinolinones (3-HQ’s).
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Planned Synthesis of Aza-Rocaglates.
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Attempted (3+2) Photocycloaddition of 12.
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A Synthesis of N-Me-3-HQ 15; B. Proposed Mechanism; C. DFT Model of Intermediate 
14d (B3LYP_6–31G**++).
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(3+2) Photocycloaddition and Prototype Synthesis of an Aza-Rocaglate.
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Methylation of an N-H-3-hydroxyquinolinone.
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Synthesis of an Advanced N-methyl-aza-rocaglate 27.
Wang et al. Page 18






















Synthesis of N-H-aza-rocaglate 5.
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